Gerresheimer (OTCMKTS:GRRMF – Get Free Report) is expected to announce its results on Wednesday, November 25th. Analysts expect the company to announce earnings of $0.7920 per share and revenue of $689.40 million for the quarter.
Gerresheimer Price Performance
Shares of Gerresheimer stock opened at $37.47 on Wednesday. The company has a fifty day moving average price of $33.04 and a 200 day moving average price of $29.64. Gerresheimer has a twelve month low of $19.16 and a twelve month high of $37.47.
Analysts Set New Price Targets
Several research firms have commented on GRRMF. UBS Group raised Gerresheimer from a “sell” rating to a “neutral” rating in a research report on Tuesday, August 4th. Deutsche Bank reaffirmed a “hold” rating on shares of Gerresheimer in a research report on Tuesday, August 4th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.
Gerresheimer Company Profile
Gerresheimer AG is a Germany-based manufacturer of pharmaceutical and healthcare packaging and drug-delivery systems. The company develops and produces primary packaging and components used to protect, store and administer medicines, serving pharmaceutical, biotechnology and healthcare customers worldwide. Its product portfolio includes glass and plastic containers such as vials, ampoules, bottles, cartridges and syringes, as well as delivery systems including inhalers, injection pens, autoinjectors and other medical devices.
Read More
- Five stocks we like better than Gerresheimer
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.
